Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3405105 in Participants With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Phase 1 a:~* Have histological or cytological evidence of a diagnosis of a solid tumor cancer that is advanced and/or metastatic~* Have available archived tissue for exploratory biomarker analysis~* Have adequate organ function~* Have discontinued all previous treatments for cancer and recovered from their side effects~* Are able to swallow capsules/tablets~Phase 1 b:~* Cohort 1: Triple-negative breast cancer (TNBC).~* Cohort 2: Clear cell ovarian cancer, endometrioid ovarian cancer, or endometrioid endometrial carcinoma with a LOF mutation in one or more of the following genes: ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).~* Cohort 3: Soft tissue sarcoma or sarcomatoid/rhabdoid malignancy with loss of expression of INI1, BRG1, or BRM by immunohistochemistry or a LOF mutation in one or more of the following genes: ARID1A, SMARCA2, SMARCA4, or SMARCB1. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 3. Participants with synovial sarcoma and a confirmed SS18-SSX gene fusion are also eligible.~* Cohort 4: Epithelioid sarcoma with INI1 loss of expression by immunohistochemistry or SMARCB1 LOF mutation. Participants aged ≥ 12 years with a body weight of ≥ 40 kilogram (kg) are acceptable for Cohorts 4.~* Cohort 5: Bladder cancer with a LOF mutation in one or more of the following genes: ARID1A, KMT2C (MLL3), KMT2D (MLL2), or KDM6A (UTX).~Exclusion Criteria:~* Have symptomatic central nervous system (CNS) malignancy or metastasis~* Have symptomatic human immunodeficiency virus (HIV), Hepatitis A, B, or C~* Have congestive heart failure~* Are breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3405105 (Type: EXPERIMENTAL): LY3405105 administered orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).